Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Muir

Showing results (131-140 of 187) with videos related to

Pageof 19
Sort By:
Pharmacogenetics and Genomics|September 25, 2013
Predictors of consent to pharmacogenomics testing in the IDEAL studyAlison B Jazwinski, Paul J Clark, Alexander J Thompson, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitisMichael Trauner, Yevgeniy Gindin, Zhaoshi Jiang, et al.
Hepatology (Baltimore, Md.)|October 5, 2010
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotypeAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Hepatology Communications|July 5, 2024
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitisDouglas Thorburn, Diana J Leeming, William T Barchuk, et al.
Molecular Genetics and Metabolism Reports|November 25, 2021
A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type IIIGhada Hijazi, Anna Paschall, Sarah P Young, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic responseZiad F Gellad, Andrew J Muir, John G McHutchison, et al.
Gastroenterology|June 16, 2010
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionAlexander J Thompson, Jacques Fellay, Keyur Patel, et al.
Nature|August 18, 2009
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceDongliang Ge, Jacques Fellay, Alexander J Thompson, et al.
Journal of Gastroenterology and Hepatology|March 18, 2015
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapyEdoardo G Giannini, Nezam H Afdhal, Samuel H Sigal, et al.
Hepatology Communications|August 28, 2023
Parental leave, childcare policies, and workplace bias for hepatology professionals: A national surveyLauren D Feld, Monika Sarkar, Jennifer S Au, et al.
Pageof 19

Showing results (131-140 of 187) with videos related to

Sort By:
Pageof 19
Pharmacogenetics and Genomics|September 25, 2013
Predictors of consent to pharmacogenomics testing in the IDEAL studyAlison B Jazwinski, Paul J Clark, Alexander J Thompson, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitisMichael Trauner, Yevgeniy Gindin, Zhaoshi Jiang, et al.
Hepatology (Baltimore, Md.)|October 5, 2010
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotypeAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Hepatology Communications|July 5, 2024
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitisDouglas Thorburn, Diana J Leeming, William T Barchuk, et al.
Molecular Genetics and Metabolism Reports|November 25, 2021
A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type IIIGhada Hijazi, Anna Paschall, Sarah P Young, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic responseZiad F Gellad, Andrew J Muir, John G McHutchison, et al.
Gastroenterology|June 16, 2010
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionAlexander J Thompson, Jacques Fellay, Keyur Patel, et al.
Nature|August 18, 2009
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceDongliang Ge, Jacques Fellay, Alexander J Thompson, et al.
Journal of Gastroenterology and Hepatology|March 18, 2015
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapyEdoardo G Giannini, Nezam H Afdhal, Samuel H Sigal, et al.
Hepatology Communications|August 28, 2023
Parental leave, childcare policies, and workplace bias for hepatology professionals: A national surveyLauren D Feld, Monika Sarkar, Jennifer S Au, et al.
Pageof 19